Analyst Price Targets — SION
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 4:46 pm | Yatin Suneja | Guggenheim | $50.00 | $34.40 | StreetInsider | Sionna Therapeutics (SION) PT Raised to $50 at Guggenheim following FY25 earnings report |
| January 7, 2026 12:09 pm | Kambiz Yazdi | BTIG | $58.00 | $37.22 | TheFly | Sionna Therapeutics price target raised to $58 from $50 at BTIG |
| January 5, 2026 11:24 am | Chris Raymond | Raymond James | $53.00 | $39.21 | StreetInsider | Sionna Therapeutics (SION) PT Raised to $53 at Raymond James |
| December 1, 2025 10:37 am | — | RBC Capital | $24.00 | $43.57 | TheFly | Sionna downgraded to Underperform from Sector Perform at RBC Capital |
| September 3, 2025 9:27 am | Brian Abrahams | RBC Capital | $22.00 | $26.19 | TheFly | Sionna Therapeutics initiated with a Sector Perform at RBC Capital |
| September 2, 2025 8:44 pm | — | Raymond James | $45.00 | $25.39 | TheFly | Sionna Therapeutics initiated with a Strong Buy at Raymond James |
| March 4, 2025 9:54 am | — | Guggenheim | $45.00 | $14.80 | TheFly | Sionna Therapeutics initiated with a Buy at Guggenheim |
Latest News for SION
WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one…
Jennifer Fitzpatrick sold 10,250 shares for a total of approximately $347,000 on March 5, 2026. This transaction represented 100.00% of her direct common stock holdings, reducing direct ownership of common stock to zero.
Superstring Capital Management acquired 180,593 shares of Sionna Therapeutics in the fourth quarter. The quarter-end position value rose by $7.43 million, reflecting the purchase of a new position.
OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in the fourth quarter; the estimated transaction value was $5.43 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $37.56 million, reflecting both trading and stock price movement.
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SION.
U.S. House Trading
No House trades found for SION.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.